Junhemeng is a recombinant protein drug developer. Junhemeng has built a drug-ready and innovative recombinant protein drug development platform, covering the high-efficiency expression system of recombinant protein, unique micro-denaturation separation and purification technology, protein in vitro High barriers such as folding and self-assembly systems, as well as long-term slow-release technology, have achieved industrialized technical reserves. Recently, Junhemeng completed the first round of A round of financing. This round of financing was jointly led by Tonghua SDIC and Lightpoint Capital, followed by Zhonghe Oppo, Focus Fund, Hongshi Capital, etc. Kaicheng Capital served as the exclusive financial advisor for this round of financing. . The funds raised from this round of financing will be mainly used for the rapid advancement of the company’s product pipeline and the construction of GMP commercial production bases.
This article is reproduced from: https://www.itjuzi.com/investevent/13586885
This site is for inclusion only, and the copyright belongs to the original author.